Search Results (1 to 10 of 1996 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 553 Journal of Medical Internet Research
- 384 JMIR Research Protocols
- 201 JMIR Formative Research
- 139 JMIR mHealth and uHealth
- 92 JMIR Public Health and Surveillance
- 87 JMIR Mental Health
- 76 JMIR Medical Informatics
- 74 Online Journal of Public Health Informatics
- 54 JMIR Human Factors
- 42 JMIR Cancer
- 35 JMIR Dermatology
- 33 JMIR Aging
- 28 JMIR Medical Education
- 28 JMIR Pediatrics and Parenting
- 24 JMIR Cardio
- 23 JMIR Serious Games
- 19 Iproceedings
- 19 JMIR Diabetes
- 15 Interactive Journal of Medical Research
- 14 JMIR Infodemiology
- 10 JMIR Perioperative Medicine
- 9 JMIR AI
- 9 JMIR Rehabilitation and Assistive Technologies
- 7 Journal of Participatory Medicine
- 6 JMIRx Med
- 5 JMIR Nursing
- 3 JMIR Neurotechnology
- 3 JMIR XR and Spatial Computing (JMXR)
- 2 JMIR Biomedical Engineering
- 1 JMIR Bioinformatics and Biotechnology
- 1 Medicine 2.0
- 0 iProceedings
- 0 JMIR Preprints
- 0 JMIR Challenges
- 0 JMIR Data
- 0 JMIRx Bio
- 0 Transfer Hub (manuscript eXchange)
- 0 Asian/Pacific Island Nursing Journal
Go back to the top of the page Skip and go to footer section
Go back to the top of the page Skip and go to footer section
It was administered in doses ranging between 0.01 and 0.1 g/kg, 3 times daily either orally or intravenously (equivalent to 2.4-24 g/d for an 80 kg patient). Among patients with schizophrenia and catatonia, approximately 30 participants, the study showed a reduction of catatonic symptoms ranging from 60% to 70%. Specifically, there were improvements in anxiety, agitation, and restlessness.
JMIR Res Protoc 2025;14:e68356
Download Citation: END BibTex RIS
Example screenshots of the Study Management and Retention Tool (SMa RT) web application, including the different Combine intervention content sections: (A) log in screen, (B) study timeline, (C) intervention content home screen, (D), health resources section, (E) frequently asked questions about pre-exposure prophylaxis.
This section includes the major time points of the study (baseline, month 6, month 12, month 18, and month 24). It allows participants to see upcoming and previously completed surveys.
JMIR Res Protoc 2025;14:e69540
Download Citation: END BibTex RIS
Go back to the top of the page Skip and go to footer section
Go back to the top of the page Skip and go to footer section
Natural Language Processing for Identification of Hospitalized People Who Use Drugs: Cohort Study
The presence of any of the following criteria (ie, abbreviated with the letters B, D, M, and N) were used to qualify the hospitalizations for inclusion in the PWUD cohort:
B (Biomarkers): In line with a previous study, positive urine toxicology for drugs or medications for SUD (eg, cocaine, amphetamine, methadone, suboxone, fentanyl, opiate, oxycodone), positive HCV antibody with positive or quantifiable HCV viral load [29]
D (Diagnostic codes): Presence of ICD-9 and or ICD-10 code for overdose, substance use
JMIR AI 2025;4:e63147
Download Citation: END BibTex RIS
Go back to the top of the page Skip and go to footer section
Go back to the top of the page Skip and go to footer section